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CoSt-EffECtivEnESS CoMPariSon of DEnoSuMab anD ZolEDroniC aCiD 
in thE trEatMEnt of PoStMEnoPauSal oStEoPoroSiS
Ding Y.1, Hay J.2
1University Of Southern California, Los Angeles, CA, USA, 2University of Southern California, Los 
Angeles, CA, USA
Objectives: To evaluate the cost-effectiveness of denosumab (Prolia®, 60 mg every 
6 month) compared to generic zoledronic acid (5 mg once yearly) in the treatment 
of postmenopausal osteoporosis in the U.S. societal perspective. MethOds: 
Comprehensive literature and online search was employed to obtain data on the 
clinical effectiveness of drugs, health-related quality of life (HRQoL) of disease 
states and costs. Databases searched were PubMed and Google Scholar engine. A 
Markov cohort model was constructed within the framework of incremental cost 
effectiveness ratios (ICERs) and net monetary benefit analyses. Given that generic 
zoledronic acid dominates denosumab in the base-case scenario, only one-way 
sensitivity analyses were performed to evaluate the sensitivity of results to model 
parameters. Finally, threshold analyses were used to determine the price at which 
denosumab would be as cost-effective as generic zoledronic acid. Results: In the 
base-case scenario, generic zoledronic acid increased 0.003 QALYs and decreased 
$227 costs incrementally compared to denosumab. Assuming a willingness-to-pay 
threshold of $150,000 per QALY, the NMB value of generic zoledronic acid compared 
to denosumab was $679. In the one-way sensitivity analyses, generic zoledronic 
acid dominated denosumab in all scenarios when model parameters were var-
ied within a range of 10% -15%. The threshold analyses indicated that even at a 
zero price, denosumab would not be cost effective relative to generic zoledronic 
acid. cOnclusiOns: Based on a U.S. societal perspective, generic zoledronic acid 
is more cost-effective than denosumab in the treatment of high-risk patients with 
postmenopausal osteoporosis.
PMS37
CoSt-utility of CElECoxib CoMParED to othEr nSaiDS for thE 
trEatMEnt of oStEoarthritiS in ChilE
Leisewitz T.1, Mould J.F.2, Bryon A.3, Copetta C.1, Said J.C.1
1HEORT, Santiago, Chile, 2Pfizer, Inc., New York, NY, USA, 3HEORT, Miami, FL, USA
Osteoarthritis (OA) is the most common joint disease in the Chilean population, 
and its treatment is guaranteed under a governmental program called “Explicit 
Health Guarantees” (GES). The chronic use of the drugs covered, non-steroidal 
anti-inflammatory (NSAIDs) and selective COX-2 inhibitors, is associated with 
gastrointestinal and cardiovascular complications. Objectives: To estimate the 
incremental cost-effectiveness ratio (ICER) of treating patients 65 years old (y/o) 
and older with Celecoxib compared to NSAIDs. MethOds: A cost-utility analysis 
was performed using a Markov model. Effectiveness data and likelihood of adverse 
events were extracted from CONDOR, MEDAL, CLASS and TARGET studies. Resource 
use was obtained from the recommendations of clinical guidelines. Unit costs were 
extracted from Chilean secondary databases or costs studies (September 2012). 
Target population: Patients 65+ y/o with mild to moderate OA. Perspective: Chilean 
public health system. Interventions: Acetaminophen, Diclofenac, Celecoxib, and 
association with proton pump inhibitor (PPI: Omeprazole). Time horizon: 6 months 
for base case. Outcome: incremental cost per quality-adjusted life year (QALY). Costs 
were measured in Chilean pesos, and converted to USD. Sensitivity analyses were 
performed, including treatment period (3-24 month), age (55-65 y/o), eliminating 
cardiovascular benefits, among others. Results: The gained QALYs for Diclofenac, 
Acetaminophen and Celecoxib were 0.31, 0.33 and 0.37 respectively (0.35, 0.34 and 
0.40 QALYs for Celecoxib+PPI). Considering the cost of care and complications, com-
pared to Acetaminophen, Celecoxib reported an ICER of USD 3497/QALY (USD 1780/
QALY for Celecoxib+PPI). Compared to Diclofenac+PPI, the ICERs for Celecoxib and 
Celecoxib+PPI were USD 8408/QALY and USD 2778/QALY. The ICERs decrease slightly 
if the time horizon increases to 1 or 3 years. All these ICERs were under the Chilean 
GDP per capita. cOnclusiOns: Using Celecoxib for OA is highly cost-effective com-
pared to other NSAIDs in the Chilean context, according to WHO recommendation, 
due to the lower incidence of complications.
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Objectives: In cost-effectiveness analysis, it is often necessary to characterize 
the incidence of events in patients with and without risk factors. Yet, the needed 
background incidence for patients without risk factors (incidence_no_risk) may be 
unavailable in the published literature. Previously, researchers have used the gen-
eral population incidence (incidence_pop), derived from epidemiological studies. 
However, when incidence_pop is used the model will overestimate the true inci-
dence because incidence_pop is a weighted average of the incidences in patients 
with and without risk factors. The purpose of this study was to develop a general 
method for deriving a true baseline risk (incidence_no_risk) using a downward 
adjustment of incidence_pop. This is illustrated with the condition of osteoporo-
sis. MethOds: In osteoporosis, the fracture incidence for high-risk persons (inci-
dence_risk) can be calculated by the patient’s baseline risk times the relative risk 
increase (RR_risk) due to risk factors (incidence_risk = incidence_no_risk*RR_risk). 
Published studies report RR_risk, incidence_pop, and the prevalence of the risk 
factor (p). The fracture incidence in the study population can be represented as 
follows: incidence_pop = incidence_risk*p + incidence_no_risk*(1-p). Therefore: 
incidence_pop = incidence_no_risk*RR_risk*p + incidence_no_risk*(1-p) incidence_
pop = incidence_no_risk*((RR_risk*p)+(1-p)) incidence_pop/((RR_risk*p)+(1-p)) = 
incidence_no_risk Results: The resulting equation is: incidence_no_risk = inci-
dence_pop/((RR_risk*p)+(1-p)). We tested incidence_pop as the baseline fracture 
incidence in an osteoporosis model, which had consistently overestimated the true 
MarketScan® Commercial Database from January 2009-July 2013. The patient’s 
first biologic claim (index claim) defined their treatment cohort. Patients were 
required to have continuous enrollment 6-months prior and 24-months follow-
ing their index claim and have a pre-index RA diagnosis. Patients with pre-index 
biologic use (including ustekinumab) or a diagnosis for other conditions that the 
study biologics are approved for were excluded. Effectiveness was estimated using 
a validated, published claims-based algorithm. Medications were considered effec-
tive until any of the following criteria were met; biologic dose escalation, switching 
biologics, adding a new non-biologic RA medication, receiving > 1 intra-articular 
injection, adding a glucocorticoid, increasing glucocorticoid dose, or low treatment 
compliance (< 80%). Each failure event had a 90-day non-response period and 
patients could experience multiple failure events over the follow-up. Costs were 
the sum of RA-related medical, pharmacy, and drug administration costs post-index 
and were attributed based on the index biologic. Cost per patient-year in response 
was defined as RA-related costs divided by the time in response. Results: 8,193 
patients (mean age = 49, 78% female) met the selection criteria. Cost per year in 
response was lower for etanercept ($26,610) compared with abatacept ($40,457, 
p< 0.001), adalimumab ($28,031, p= 0.003), golimumab ($28,722, p= 0.030), and inf-
liximab ($40,507, p< 0.001). Certolizumab also had numerically higher cost per 
patient-year in response ($28,486) compared to etanercept; however, this was not 
statistically significant (p= 0.141), possibly due to a smaller sample size for certoli-
zumab (n= 184). cOnclusiOns: Using this algorithm, etanercept was estimated as 
the most cost-effective RA biologic with the lowest cost per patient-year in response 
among FDA-approved biologics for RA.
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Objectives: Rheumatoid Arthritis (RA) affects approximately 0.4% of the Latin 
American population over 16 years of age. [1] Decreased pain and disability pre-
vention may be possible with a early diagnosis and appropriate treatment. [2] The 
objective is to assess the cost-effectiveness (CE) of Etanercept in the treatment for 
moderate to severe RA, with previous antirheumatic drugs failure, in comparison 
with the rest of anti-TNF and IL-6 blockers available in Dominican Republic, from the 
health care payer’s perspective. MethOds: A decision tree model was implemented 
to compare the costs and effectiveness of Etanercept (comparator, 25mg/ 2 times 
per week), Adalimumab (40mg/every two weeks), Infliximab (3 mg/kg at 0, 2 and 
6 weeks, then every 8 weeks), Rituximab (1000mg day 0 and 15, with reevaluation 
every 24 weeks) and Tocilizumab (8mg/kg every 4 weeks), all in combination with 
Methotrexate. The effectiveness measures were: American College of Rheumatology 
(ACR) Response Criteria ACR20 and ACR70. Quality utilities were obtained from 
Health Assessment Questionnaire (HAQ). Local costs (2013 US$) were obtained from 
Local Public Health databases. The outcomes were: total costs of RA (adverse events, 
exams and treatments) and QALYs gained. Probabilistic sensitivity analysis was 
performed. The time horizon was 2 years and the discount rate was 5% for costs 
and health outcomes. Results: The total cost of Etanercept was $US30,355.46, 
being $US1,968.70, $US175.92, $US3,930.32, and $US11,260.72 less expensive than 
Adalimumab, Infliximab, Tocilizumab and Rituximab respectively. Etanercept also 
gained the highest number of QALYs (1.5423) in comparison with adalimumab 
(1.5048), infliximab, (1.4299), tocilizumab (1.4955) and rituximab (1.4674). Cost-
effectiveness analyses showed Etanercept as the dominant strategy. Acceptability 
curves showed that at the willingness-to-pay of US$17200/QALY, the probability that 
etanercept is cost-effective met 100%. [3] cOnclusiOns: Etanercept appeared as 
the most cost-effective alternative for RA against other anti-TNF and IL-6 blockers 
in Dominican Republic.
PMS35
rituxiMab aS firSt ChoiCE for PatiEntS With rEfraCtory rhEuMatoiD 
arthritiS: a SyStEMatiC rEviEW anD CoSt-EffECtivEnESS analySiS
Ahmadiani S., Nikfar S., Karimi S., Jamshidi AR, Kebriaeezadeh A., Akbari-Sari A.
Tehran University of Medical Sciences, Tehran, Iran
Objectives: Using rituximab for patients with rheumatoid arthritis who are 
refractory to conventional and/or biologic “disease modifying anti-rheumatic 
drugs” (DMARDs) is common choice of therapy in Iran. We evaluated the effec-
tiveness and cost-effectiveness of using rituximab for these patients in compari-
son to continuing conventional DMARDs, from a perspective of health service 
governors. MethOds: A systematic review was implemented through search-
ing MEDLINE, Scopus and Cochrane Library. Inclusion criteria were being an RCT 
on rituximab, for refractory rheumatoid arthritis patients, and with a control 
group of DMARDs. Included articles were qualified by JADAD questionnaire. Risk 
Difference and CI95 were calculated and heterogeneity was tested by the Cochran 
Q test. To measure the direct and indirect medical costs, a set of interviews with 
patients were applied. Thirty two patients were selected from three referral clin-
ics in Tehran with definite diagnosis of refractory rheumatoid arthritis in the 
year before, and treatment regimen of either rituximab or DMARDs within last 
year. Incremental cost-effectiveness ratio was calculated using mean of costs 
for 6 months period and risk difference, with a scenario and sensitivity analy-
sis. Results: From 1875 related articles, 4 studies were eligible to be considered 
in this systematic review. Results of meta-analysis showed homogeneity of all 4 
studies and a total risk difference of 0.3 for ACR20 criteria, 0.2 for ACR70WR, and 
0.37 for EULAR criteria of response. Also mean of total medical costs of patients 
for one year were $7957 in rituximab group and $1861 for DMARDs group. Hence, 
the cost-effectiveness ratio will be $10159 per ACR20, $15238 per ACR70WR, and 
$8237 per EULAR in base case analysis, while in generic rituximab scenario shows 
a 30% reduction of results. cOnclusiOns: Rituximab for patients with refractory 
rheumatoid arthritis does not seem to be cost-effective in Iran, although generic 
use of this drug can be encouraged.
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cal response to short and long term treatment, based on all available randomized 
controlled trials (and indirect comparisons, where appropriate). All costs, in 2012 
Colombian pesos (1 USD$ = COP$1800) were obtained locally, using official databases 
for drug costs, and tariff manual (ISS 2001+30%) for procedures and complications. 
HAQ scores were used to calculate utilities, measured in QALYs. Annual discount 
rate was 3% both for cost outcomes. Results: Total costs, in million COP$, for the 
first year of treatment were $25.51 for adalimumab, $26.96 for certolizumab, $26.94 
for etanercept, $34.79 for golimumab, $25.63 for infliximab and $22.71 for tofacitinib. 
Tofacitinib represented a 16% cost reduction over a market-share weighted average 
of biological therapy in the first year, with equivalent or slightly better QALY gain 
(0.62 vs. 0.61). Cost savings and utility gained were maintained, and dominance was 
attained in more than 50% of Monte Carlo trials in the different time horizons and 
against all comparators considered. cOnclusiOns: Under our model assumptions, 
and current costs in Colombia, for the national health care system, the sequence 
initiating with tofacitinib is a cost-saving alternative compared with biological 
therapy after failure to methotrexate in adults with rheumatoid arthritis, attaining 
at least the same average effectiveness in all the different time horizons considered.
PMS42
CoSt-EffECtivEnESS of aDaliMuMab for rhEuMatoiD arthritiS in 
gErMany
Gissel C.
Justus Liebig University, Giessen, Germany
Objectives: Rheumatoid Arthritis (RA) can be treated with TNFα inhibitors after the 
failure of conventional disease-modifying antirheumatic drugs like methotrexate. The 
percentage of German patients treated with TNFα inhibitors has been rising from 2 
% in 2000 to 20 % in 2008. In 2012, adalimumab was the most popular TNFα inhibitor 
and the best selling drug in the German statutory health insurance system with net 
expenditure of 581 mn € . We aim to analyze the cost-effectiveness of adalimumab for 
the treatment of RA in Germany. MethOds: We set up a Markov Chain Monte Carlo 
lifetime model to simulate 10,000 hypothetical patients. Initially, patients can achieve 
one of three responses according to American College of Rheumatology criteria or 
fail the therapy. Each response is associated with an initial improvement in func-
tional status. In each cycle, treatment might be discontinued due to loss of efficacy 
or adverse events. Results: In the base case, patients gain 2.64 quality-adjusted 
life years (QALYs) with methotrexate monotherapy and 6.25 QALYs if adalimumab 
combination therapy is added to the treatment algorithm. The incremental cost-utility 
ratio (ICUR) is 32,210 € based on German list prices. After deduction of mandatory 
rebates and taxes, the ICUR is only 23,755 € . Adalimumab combination therapy low-
ers indirect cost from 295,070 € to 235,531 € . The ICUR based on total cost is 15,728 € 
(7,274 € after deducting taxes and rebates). ICURs further improve for younger baseline 
age. Limiting the simulation time to 5 or 10 years increases ICURs. cOnclusiOns: 
Adalimumab therapy for the treatment of RA is cost-effective in Germany even in the 
base case scenario, which uses incorrectly high list prices and ignores indirect cost 
savings. Our analysis shows that cost-effectiveness analysis of drugs for chronic dis-
eases need to consider indirect costs and need to take a lifetime modeling perspective.
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hEalth CarE ExPEnDiturES aSSoCiatED With DEPrESSion aMong 
inDiviDualS With oStEoarthritiS: PoSt-rEgrESSion linEar 
DECoMPoSition aPProaCh
Agarwal P., Sambamoorthi U.
West Virginia University, Morgantown, WV, USA
Objectives: Osteoarthritis commonly co-occurs with depression leading to poor 
health outcomes and high economic burden. The objective was to examine the con-
tributing factors to excess total health care expenditures associated with depres-
sion among those with osteoarthritis using a post-regression linear decomposition 
approach. MethOds: Data were derived from the 2010 Medical Expenditure Panel 
Survey (MEPS) and self-reported osteoarthritis and depression were identified. Chi-
square tests and ordinary least square regressions (OLS) on log-transformed expen-
ditures were used to determine the association between depression status and 
health care expenditures after controlling for predisposing (gender, race, and age), 
enabling (marital status, education, employment, poverty status, insurance cover-
age, and usual source of care), need (perceived physical and mental health, anxi-
ety, presence of cardiovascular conditions, and other chronic conditions), lifestyle 
(Body-Mass index, exercise, and smoking status), and external environment factors 
(metro versus non-metro). Post-regression linear decomposition technique was used 
to estimate the relative contribution of individual-level variables to the excess expen-
ditures associated with depression and osteoarthritis compared to those without 
depression. Results: Among individuals with osteoarthritis 20.6% reported having 
depression. The average total health care expenditures were $13,684 for those with 
depression compared to $9,284 among those without depression. OLS regression on 
log-transformed total health care expenditures revealed that those with depression 
had 38.8% greater health care expenditures (p < 0.001) compared to adults without 
depression. Post-regression linear decomposition analysis indicated that nearly 50% 
of the difference in average health care expenditures among adults with and without 
depression can be explained by differences in individual-level characteristics between 
the two groups. These differences may be attributable mainly to the need factors 
such as perceived health status, anxiety, presence of cardiovascular conditions, and 
other chronic conditions. cOnclusiOns: Results from the study suggest that excess 
health care expenditures associated with depression may be reduced by improving 
the co-management of chronic physical and mental health conditions.
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rESourCE uSE rElatED to vErtEbral fraCturES baSED on Data froM 
iCuroS
Svedbom A1, Wintzell V.2, Alekna V.3, Bianchi M.L.4, Clark P.5, Díaz-Curiel M.6, Dimai H.P.7, 
Lesnyak O.8, McCloskey E.9, Sanders K.M.10, Tamulaitiene M.3, Thomas T.11, Borgström F.12, 
Kanis J.A.13
fracture incidence. For example, the published incidence_pop for spinal fractures 
for males age 80-84 is reported as 3.58/1,000 patient-years. When incidence_pop is 
used as incidence_no_risk, our model predicted 6.89 spinal fractures/1,000 patient-
years. After adjustment, the model predicted the fracture incidence accurately 
as 3.45/1,000 patient-years. cOnclusiOns: The fracture incidence in non-risk 
patients, the baseline incidence used in the model, can be calculated using this 
method based on the fracture incidence from the study population, the risk factor 
prevalence, and the relative risk increase associated with the risk factor.
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thE CoSt-EffECtivEnESS of altErnativE trEatMEnt SEquEnCES in 
rhEuMatoiD arthritiS
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Objectives: Many patients with rheumatoid arthritis (RA) fail to respond ade-
quately to first-line therapy with conventional disease-modifying antirheumatic 
drugs (cDMARDs). Biologic disease-modifying antirheumatic drugs (bDMARDs) 
have improved outcomes, and multiple guidelines National Institute for Health 
and Care Excellence (NICE) govern their prescription in England and Wales. The 
study objective was to estimate the cost-effectiveness of treatment sequences of 
alternative bDMARDs versus cDMARDs in patients who have failed to respond to 
at least two cDMARDs. MethOds: A discrete event simulation model was used 
to explore the cost-effectiveness of bDMARDs in combination with methotrexate 
versus cDMARDs. Populations of interest were patients with severe and moderate 
to severe RA who failed to respond to at least two cDMARDs including methotrex-
ate (cDMARD-IR). In the severe population, eight alternative bDMARD strategies 
and one cDMARD strategy were considered. In the moderate population, a single 
bDMARD strategy was compared against a cDMARD strategy. Strategies evaluated 
differed by the therapy with which the strategy began (a bDMARD or cDMARDs) 
and thereafter were based on current NICE guidance. The perspective was that of 
the UK National Health Service and Personal Social Services. The main outcome 
was the incremental cost-effectiveness ratio (ICER, expressed as cost per quality-
adjusted life years). Results: In a severe population, etanercept resulted in an 
ICER of £20,520 versus a cDMARD strategy (7 strategies strictly or extendedly domi-
nated). In a moderate to severe population the ICER for the etanercept strategy 
was £24,727 versus the cDMARD strategy. In probabilistic sensitivity analysis, the 
etanercept strategy had the highest probability of being cost-effective at a thresh-
old of £30,000. cOnclusiOns: Based on the results of this analysis, a treatment 
strategy beginning with etanercept was considered to be the most cost-effective in 
patients with severe and moderate to severe RA who failed to respond to at least 
two conventional DMARDs.
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Objectives: Following a recent price regulation for biopharmaceutical products 
in Colombia, we aimed to determine the impact on the cost of treatment with bio-
logic therapies for rheumatoid arthritis in patients who failed to respond to oral 
DMARDS. MethOds: Current guidelines and evidence suggest similar efficacy and 
safety among 7 biologic products available in Colombia for the treatment of rheu-
matoid arthritis following DMARD failure: abatacept, adalimumab, certolizumab, 
etanercept, golimumab, infliximab and tocilizumab. We compared the annual direct 
medical cost of treatment (including drug costs, administration and monitoring) 
for intravenous (IV) and subcutaneous (SC) injections of these biologics. Dosages 
were determined based on the approved product labels and the average weight (62 
Kg) for a cohort of 275 patients with rheumatoid arthritis from a private institu-
tion in Bogota, Colombia. Costs were calculated using the data from most current 
price regulation guidance from the Ministry of Health (Circular 04-05/2013) and 
official sources for payments of treatments and procedures (SISMED). Sensitivity 
analyses were performed using different dosages and patients’ weights. Results: 
Direct annual cost of treatment with biologics was higher in the first year than in 
subsequent years, except for tocilizumab, etarnercept, adalimumab and golimumab 
which do not need additional dosages in the first year. Abatacept, both IV and SC, 
consistently showed the lowest direct medical cost after 3 years. The additional cost 
of treatment with other biologic therapies compared to abatacept ranged from 11% 
to 48% after 3 years. Despite having additional costs of administration, IV biologics 
had lower total direct medical cost compared to SC, mainly due to higher cost per 
dosage of the drugs. cOnclusiOns: Under the current price regulation for biolog-
ics in Colombia, the cost of treatment for rheumatoid arthritis favors the use of 
abatacept as a first line biologic after DMARD failure.
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EConoMiC Evaluation of tofaCitinib CoMParED With biologiCal 
thEraPy aS initial MEDiCation aftEr failurE to MEthotrExatE in 
aDultS With rhEuMatoiD arthritiS in ColoMbia
Rosselli D., Rueda J.D., Tarazona N., Díaz C.E.
Pontificia Universidad Javeriana, Bogotá, Colombia
Objectives: To compare, from the Colombian health care system perspective, both 
costs and effectiveness of tofacitinib with biological therapy as initial treatment in 
adults with rheumatoid arthritis after failure to methotrexate. MethOds: We used 
an Excel-based patient level simulation model to compare, with different time hori-
zons (1, 2, 3 , 5, 10, and 20 years), cohorts of patients with tofacitinib as initial therapy 
compared with adalimumab, certolizumab, etanercept, golimumab or infliximab. 
All the patients modeled received concomitant treatment with methotrexate. The 
characteristics of the patients included: age, weight, initial HAQ score, and clini-
